BioSpace News Archive

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Protocol First, Inc., a software solutions provider focused on accelerating clinical research, today announced a novel strategic partnership aimed at driving faster, more efficient clinical trials

YishengBio Co., Ltd. (“YishengBio”, the “Company”) announced today the closing of a US$130 million in Series B funding round. The new investment was co-led by Oceanpine and OrbiMed. After completing the Series B funding round, the company’s institutional investors include: OrbiMed, Oceanpine, EightRoad, F-Prime Capital, 3W Capital,

JDRF International, the Lupus Research Alliance and the National Multiple Sclerosis Society joined forces to accelerate research and discovery in autoimmunity and are proud to announce the recipients of their first joint grants.

Today, the Tuberous Sclerosis Alliance (TS Alliance) and Nobelpharma America, LLC (NPA) announced an ongoing collaboration.

Pharmaceutical Associates, Inc. (PAI) today announced the appointment of Domenic Ciarico as Chief Commercial Officer, bringing with him 25 years of industry experience to the company.

Clarus Therapeutics Inc. announced today the appointment of Richard ‘Ric’ Peterson as chief financial officer (CFO). Peterson brings to Clarus a wealth of financial leadership experience from his 25-year career in the pharmaceutical industry, where he has served as CFO of public and private companies.

ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company’s board of directors, effective immediately.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has completed the mouse immunogenicity study with transgenic mice that have been genetically engineered with a gene from the human immune system called the DR4 human leukocyte antigen (HLA) allele

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss the financial results for the year ended December 31, 2020 and provide a corporate business update on Wednesday, March 3, 2021 at 4:30pm EST/ 1:30pm PST